My point is you don't buy a controlling position in a company if your objective is to lose money. Deerfield is not making money by trading around their position.
I don't have time right now to review the data but I'm not sure if it prevents addiction or the euphoria. I know they talk about respiratory depression & constipation.
Deerfield is controlling the trading. They are trying to find buyers & the price will continue to move lower until their selling is done.
Lake Ponchartrain is north of New Orleans & I was 10 miles south of New Orleans. The storm looked like it was coming out of the southeast & blowing northwest so it had to be coming out of the gulf. I'm not a weatherman but that's what it looked like to me.
to put itself up for sale. We need Deerfield to quit being a passive investor.
Everything is positive but no details. He considers 2015 the first year of Otrexup launch. I guess the first year was an expensive practice. More excuses.
QST - Phase III trial to start in 3rd quarter.
QSM - Nothing
Epipen - Still waiting for FDA decision. Anticipate 3rd qtr. Doesn't expect a 3rd entry until 2021 at earliest. Look for 10% of generic epipen revenues going to ATRS.
Sumatriptan - Waiting for imminent approval notice.
The plate is pretty full - Doesn't plan to expand the pipeline.
On another note - Golf got caught short due to rain so I was able to make it home for the presentation.
Go to the Antares website & look at the latest presentation. They also have some new acronym for the QST study. I guess that's the big news.
Hobb's involvement with Delcath should have eliminated his consideration as president of ATRS. Who can trust the guy after that disaster?